Abbvie stock price target raised to $240 from $215 at BMO Capital

BMO Capital raised its price target on AbbVie (ABBV) to $240 from $215, maintaining an Outperform rating, following the pharmaceutical giant's settlement with generic manufacturers for its key drug Rinvoq, extending market exclusivity until 2037. This resolution is expected to drive growth beyond current consensus expectations. Further reinforcing its strategic positioning, AbbVie announced plans to acquire Gilgamesh Pharmaceuticals' psychedelic therapy for up to $1.2 billion, expanding its psychiatric drug pipeline and contributing to positive analyst sentiment.

Analysis

AbbVie's (ABBV) outlook has been significantly strengthened by recent strategic successes, prompting positive analyst revisions. BMO Capital raised its price target to $240.00 from $215.00, citing a pivotal litigation settlement for the key drug Rinvoq. This agreement extends market exclusivity by delaying generic competition until 2037, a full four years beyond the drug's primary patent expiration in 2033, which is expected to drive growth beyond current consensus. This de-risking of a core revenue stream is complemented by aggressive pipeline expansion. AbbVie's planned acquisition of Gilgamesh Pharmaceuticals' psychedelic therapy, bretisilocin, in a deal valued up to $1.2 billion, marks a significant entry into the psychiatric drug market and prompted Raymond James to reiterate its Outperform rating with a $236.00 price target. These developments are underpinned by strong fundamentals, including last-twelve-months revenue of $58.3 billion and a gross profit margin of 71.25%, and a continued commitment to shareholder returns, evidenced by a newly announced quarterly dividend of $1.64 per share.

Key Decisions for Investors

• Investors should recognize that the Rinvoq settlement significantly enhances AbbVie's long-term revenue visibility and reduces patent cliff risk, supporting a more bullish valuation model.
• The acquisition of bretisilocin represents a strategic pivot into the high-growth psychedelic therapy market, and its successful development could serve as a major future catalyst for the stock.
• Given the stock is trading near its 52-week high and multiple analysts see further upside, investors could consider the current momentum justified, while monitoring for potential pullbacks to add to positions.
• Pay attention to the execution of the Gilgamesh acquisition and future clinical trial data, as these are now critical factors for justifying the stock's premium valuation and continued outperformance.